Bausch + Lomb glaucoma eye drop fails Phase 2 trial

July 9, 2026 4:30 PM

Bausch + Lomb Corporation (NYSE/TSX: BLCO) said its Phase 2 study of BL1107, an eye drop candidate for glaucoma, did ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found